20,436 Shares in Collegium Pharmaceutical, Inc. $COLL Bought by Jennison Associates LLC

Jennison Associates LLC bought a new stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 20,436 shares of the specialty pharmaceutical company’s stock, valued at approximately $676,000. Jennison Associates LLC owned 0.06% of Collegium Pharmaceutical at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in COLL. Rubric Capital Management LP raised its stake in shares of Collegium Pharmaceutical by 5.3% during the 2nd quarter. Rubric Capital Management LP now owns 3,157,743 shares of the specialty pharmaceutical company’s stock valued at $93,374,000 after buying an additional 157,743 shares during the last quarter. Vanguard Group Inc. grew its holdings in Collegium Pharmaceutical by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 2,256,254 shares of the specialty pharmaceutical company’s stock worth $104,465,000 after acquiring an additional 29,876 shares during the period. Renaissance Technologies LLC grew its holdings in Collegium Pharmaceutical by 1.1% during the fourth quarter. Renaissance Technologies LLC now owns 1,617,349 shares of the specialty pharmaceutical company’s stock worth $74,883,000 after acquiring an additional 18,160 shares during the period. Janus Henderson Group PLC grew its holdings in Collegium Pharmaceutical by 59.1% during the fourth quarter. Janus Henderson Group PLC now owns 1,448,578 shares of the specialty pharmaceutical company’s stock worth $67,026,000 after acquiring an additional 538,337 shares during the period. Finally, Principal Financial Group Inc. raised its position in Collegium Pharmaceutical by 0.3% during the fourth quarter. Principal Financial Group Inc. now owns 1,313,662 shares of the specialty pharmaceutical company’s stock valued at $60,823,000 after acquiring an additional 3,891 shares in the last quarter.

Wall Street Analyst Weigh In

COLL has been the subject of a number of analyst reports. Zacks Research raised Collegium Pharmaceutical from a “hold” rating to a “strong-buy” rating in a report on Monday, June 29th. Wall Street Zen raised shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Truist Financial upgraded shares of Collegium Pharmaceutical to a “strong-buy” rating in a research note on Monday, June 15th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Collegium Pharmaceutical in a research note on Monday, July 6th. Two research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $57.50.

Collegium Pharmaceutical Price Performance

Shares of Collegium Pharmaceutical stock opened at $34.72 on Thursday. The company has a quick ratio of 1.62, a current ratio of 1.71 and a debt-to-equity ratio of 2.47. Collegium Pharmaceutical, Inc. has a twelve month low of $29.19 and a twelve month high of $50.79. The business has a 50-day moving average price of $34.61 and a 200 day moving average price of $38.02. The firm has a market cap of $1.13 billion, a PE ratio of 17.02 and a beta of 0.73.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings results on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.52 by $0.24. Collegium Pharmaceutical had a return on equity of 95.18% and a net margin of 9.41%.The company had revenue of $193.52 million for the quarter, compared to the consensus estimate of $184.47 million. During the same quarter in the prior year, the business posted $1.49 earnings per share. Collegium Pharmaceutical’s revenue for the quarter was up 8.9% on a year-over-year basis. Sell-side analysts predict that Collegium Pharmaceutical, Inc. will post 6.76 earnings per share for the current fiscal year.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.